Effectiveness and safety of indapamide sustained-release in the treatment of post partial hypertension

Background. Hypertensive disorders in pregnancy have been recognized as an important risk factor for atherosclerotic CVD in women. Therefore, lifestyle modifications, regular blood pressure control, and control of metabolic factors are recommended after delivery, to avoid complications in subsequent pregnancies and to reduce maternal cardiovascular risk in the future. There are no uniform recommendations for the treatment of post partial hypertension (HT) yet.Methods. In a case-control, open-label 1-year study, 54 post-partum hypertensive women (aged 22-38 years; body mass index 26.7±3.8 kg/m2; 18 with previous pre-eclampsia, 18 pre-existing HT, 18 pre-existing HT plus superimposed pre-eclampsia) were studied. Nursing mothers (n=27) received adjusted-dose methyldopa (Egis) 500-2000 mg daily, 27 non-feeding women received indapamide SR (Servier) 1.5 mg daily. No significant differences observed between two groups at baseline.Results. After comprehensive follow-up, clinical blood pressure was not found to differ substantially between indapamide and methyldopa groups (124.8±3.2/83.2±2.1 mmHg vs 125.3±3.8/81.5±2.9 mmHg respectively; p =NS), but indapamide significantly better improved diurnal BP patterns. No maternal adverse effects were registered in both groups, except for sleepiness and bad mood in 18.5% of methyldopa patients. There was a significant difference in weight reduction, in favour of indapamide (-11.3 kg vs -2.7 kg; p =0.032), as well as in decrease of microalbuminuria (-189.2 mg/24 h vs -51.4 mg/24 h; p <0.001) and left ventricular mass index (-25.3 g/m2 vs -10.5 g/m2; p =0.021). No significant changes in lipid and glucose metabolism were found in both groups. Treatment with indapamide significantly improved endothelial function, non-invasively assessed by flow-mediated dilatation of the brachial artery using high-resolution ultrasound (+9.3% vs +2.9%; p =0.041). Moreover, indapamide demonstrated a good safety profile and led to high adherence to treatment. In the methyldopa group, no reduced milk production and offspring adverse effects were observed.Conclusions. The results provide support for indapamide SR as an effective and safe therapy of hypertension after delivery. Indapamide is superior to methyldopa in women with post partial hypertension.

post-partum hypertension, indapamide SR

1. Mosca L, Benjamin E.J, Berra K et al. Effectiveness - based guidelines for the prevention of cardiovascular disease in women - 2011 update: a Guideline from the American Heart Association. Circulation 2011; 123: 1243-62.

2. Wilson B.J, Watson M.S, Prescott G.J et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003; 326: 845.

3. Ray J.G, Vermeulen M.J, Schull M.J, Redelmeier D.A. Cardiovascular health after maternal placental syndromes (CHAMPS): population - based retrospective cohort study. Lancet 2005; 366: 1797-803.

4. Mc Donald S.D, Malinowski A, Zhou Q et al. Cardiovascular sequel of preeclampsia/eclampsia: a systematic review and meta - analyses. Am Heart J 2008; 156: 918-30.

5. Regitz-Zagrosek V, Lundqvist C.B, Borghi C et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy. The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. http://doi:10.1093/eurheartj/ehr218

6. Диагностика и лечение артериальной гипертензии у беременных: клинические рекомендации. М., 2010.

7. Гайсин И.Р. Артериальная гипертензия у беременных - новый кардиоренальный континуум. Тер. архив. 2012; 84 (1): 48-53.

8. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.

9. Сидорова Н.В., Белькин Ю.А. Мониторирование артериального давления. Учебное пособие для врачей. М., 2001.

10. Weidmann P. Metabolic profile of indapamide sustained - release in patients with hypertension. Data from three randomized double - blind studies. Drug Safety 2001; 24: 1155-65.

11. Cockburn J, Moar V.A, Ounsted M, Redman C.W. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982; 1: 647-9.

12. Гайсин И.Р., Исхакова А.С., Шилина Л.В. Урсодезоксихолевая кислота в коррекции дислипидемии у кормящих грудью женщин, перенесших преэклампсию. Рос. мед. вести. 2014; 19 (1): 71-5.

13. Gosse P, Sheridan D.J, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg vs. enalapril 20 mg; the LIVE study. J Hypertens 2000; 18: 1465-75.

14. Marre M, Puig J.G, Kokot F et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22: 1613-22.

15. Глезер М.Г., Сайгитов Р.Т. Лечение женщин с артериальной гипертонией: результаты эпидемиологического исследования АФИНА. Consilium Medicum. 2009; 1: 21-9.

16. Мартынов А.И., Терновой С.К., Остроумова О.Д. и др. Особенности изменения растяжимости аорты у пожилых больных на фоне длительной терапии различными классами гипотензивных средств (по данным магнитно - резонансной томографии). Кардиология. 2002; 42 (5): 19-22.

17. Гайсин И.Р., Валеева Р.М., Шилина Л.В. и др. Структура сердечно - сосудистой патологии у беременных женщин и эффективность региональной специализированной помощи. Кардиология. 2013; 53 (2): 68-74.